GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the U.S ...

Spark’s Take on GB:GSK Stock According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform. GlaxoSmithKline’s stock is supported by strong financial performance and strategic initiatives ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma therapy approval.

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, ... Spero’s stock price was up 245.89% at last check Wednesday following the news.

Shares of GSK PLC GSK slid 4.90% to £13.79 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the FTSE 100 Index UKX falling 0.44% to 8,559.33. GSK PLC ...

GSK will be responsible for making ‘success-based’ milestone payments and tiered royalties to Novartis. GSK Stock’s Performance Year to date, shares of GSK have gained 7% against the ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, ... Price Action: GSK stock is up 1.98% at $37.07 during the premarket session at the last check on Wednesday.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, ACAD has a P/B of 4.87.

GSK’s Price Performance, Valuation & Estimate Movement. GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and ...